229 related articles for article (PubMed ID: 33622859)
21. Updates in therapy for uterine serous carcinoma.
Roque DM; Santin AD
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):29-37. PubMed ID: 23138439
[TBL] [Abstract][Full Text] [Related]
22. Uterine papillary serous carcinoma: state of the state.
Naumann RW
Curr Oncol Rep; 2008 Nov; 10(6):505-11. PubMed ID: 18928665
[TBL] [Abstract][Full Text] [Related]
23. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
24. A 4-gene signature predicts prognosis of uterine serous carcinoma.
Chen H; Li L; Qin P; Xiong H; Chen R; Zhang M; Jiang Q
BMC Cancer; 2021 Feb; 21(1):154. PubMed ID: 33579221
[TBL] [Abstract][Full Text] [Related]
25. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
26. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
27. Role of surgical staging and adjuvant treatment in uterine serous carcinoma.
Frey MK; Bashir S; Ward NM; Hensel KJ; Caputo TA; Holcomb KM; Baergen R; Gupta D
Eur J Gynaecol Oncol; 2013; 34(5):453-6. PubMed ID: 24475582
[TBL] [Abstract][Full Text] [Related]
28. In search for biomarkers and potential drug targets for uterine serous endometrial cancer.
Dinoi G; Mariani A; Martinelli E; Ciucci A; Zannoni GF; Weaver AL; Keeney GL; Vasmatzis G; Anastasiadis PZ; Fanfani F; Scambia G; Gallo D
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1647-1658. PubMed ID: 33754208
[TBL] [Abstract][Full Text] [Related]
29. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.
Sagae S; Susumu N; Viswanathan AN; Aoki D; Backes FJ; Provencher DM; Vaughan M; Creutzberg CL; Kurzeder C; Kristensen G; Lee C; Kurtz JE; Glasspool RM; Small W
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S83-9. PubMed ID: 25341586
[TBL] [Abstract][Full Text] [Related]
30. Uterine serous carcinoma: a comparison of therapy for advanced-stage disease.
Gehrig PA; Morris DE; Van Le L
Int J Gynecol Cancer; 2004; 14(3):515-20. PubMed ID: 15228426
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant chemotherapy in endometrial cancer.
Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; Casado Saenz E
Cancer Chemother Pharmacol; 2020 Mar; 85(3):477-486. PubMed ID: 31950214
[TBL] [Abstract][Full Text] [Related]
32. Distribution and volume of extrauterine disease in uterine serous carcinoma: is minimally invasive surgery a suitable approach?
Ayeni TA; AlHilli MM; Bakkum-Gamez JN; Mariani A; McGree ME; Weaver AL; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
Int J Gynecol Cancer; 2015 Jan; 25(1):87-91. PubMed ID: 25474625
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy for patients with stage I papillary serous endometrial cancer.
Alobaid A; Bruchim I; Verkooijen H; Gauthier P; Petignat P
Eur J Surg Oncol; 2006 Apr; 32(3):358-62. PubMed ID: 16414233
[TBL] [Abstract][Full Text] [Related]
34. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.
Boruta DM; Gehrig PA; Fader AN; Olawaiye AB
Gynecol Oncol; 2009 Oct; 115(1):142-153. PubMed ID: 19592079
[TBL] [Abstract][Full Text] [Related]
35. Factors prognostic of survival in advanced-stage uterine serous carcinoma.
Holman LL; Pal N; Iglesias DA; Soliman PT; Balakrishnan N; Klopp A; Broaddus RR; Fleming ND; Munsell MF; Lu KH; Westin SN
Gynecol Oncol; 2017 Jul; 146(1):27-33. PubMed ID: 28465008
[TBL] [Abstract][Full Text] [Related]
36. Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study.
Kim M; Kwon BS; Chang HK; Lee S; Chang SJ; Choi JY; Park SY; Lee M; Ryu HS; Kim YB
J Gynecol Oncol; 2019 May; 30(3):e44. PubMed ID: 30887761
[TBL] [Abstract][Full Text] [Related]
37. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
38. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Mar; 152(3):599-604. PubMed ID: 30551884
[TBL] [Abstract][Full Text] [Related]
39. Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?
Velker V; D'Souza D; Prefontaine M; McGee J; Leung E
Int J Gynecol Cancer; 2016 Mar; 26(3):491-6. PubMed ID: 26825823
[TBL] [Abstract][Full Text] [Related]
40. Uterine serous carcinoma: a historic evaluation of therapy.
de Leeuw Fa; Rijcken Fe; Trum Jw; van der Noort V; Tjon-Kon-Fat Ri; Bleeker Mc; Kenter Gg
Eur J Gynaecol Oncol; 2016; 37(2):211-5. PubMed ID: 27172747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
